共 50 条
- [41] Oncologists rationale for testing PD-L1 expression levels in patients with disease states where PD-L1 testing is not part of the IO product specific indications.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Winkelman, Daniel F.Mecham, StacyForouzan, AmirFaroun, Yacoub
- [42] Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade[J]. CLINICAL CANCER RESEARCH, 2021, 27 (24) : 6749 - 6760Terry, StephaneDalban, CecileRioux-Leclercq, NathalieAdam, JulienMeylan, MaximeBuart, StephanieBougouin, AntoineLespagnol, AlexandraDugay, FredericMoreno, Irelka ColinaLacroix, GuillaumeLorens, James B.Gausdal, GroFridman, Wolf H.Mami-Chouaib, FathiaChaput, NathalieBeuselinck, BenoitChabaud, SylvieBarros-Monteiro, JaniceVano, YannEscudier, BernardSautes-Fridman, CatherineAlbiges, LaurenceChouaib, Salem
- [43] PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials[J]. PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (03) : 245 - 253Madore, JasonVilain, Ricardo E.Menzies, Alexander M.Kakavand, HojabrWilmott, James S.Hyman, JessicaYearley, Jennifer H.Kefford, Richard F.Thompson, John F.Long, Georgina V.Hersey, PeterScolyer, Richard A.
- [44] Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Nassar, AminMouw, Kent WilliamLiu, Chia-JenLundgren, KevinVan Allen, Eliezer MendelHarshman, Lauren ChristinePomerantz, MarkPreston, Mark A.Wei, Xiao X.McGregor, Bradley AlexanderChoudhury, Atish DipankarBellmunt, JoaquimChoueiri, Toni K.Kwiatkowski, David J.Sonpavde, Guru
- [45] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532Liu, Y.Cao, L.Che, X.Qiu, X.Li, Z.Yang, B.Wang, S.Qu, X.
- [46] Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)Suszczyk, DorotaSkiba, WiktoriaZardzewialy, WitoldPawlowska, AnnaWlodarczyk, KarolinaPolak, GrzegorzTarkowski, RafalWertel, Iwona
- [47] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis[J]. CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292Yang, YaoChen, DongboZhao, BigengRen, LiyingHuang, RuiFeng, BoChen, Hongsong
- [48] The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents[J]. Cancer Immunology, Immunotherapy, 2022, 71 : 1823 - 1835Carlos Zamora AtenzaGeòrgia AngueraMariona Riudavets MeliàLetícia Alserawan De LamoIvana SullivanAndrés Barba JoaquinJorgina Serra LopezM. Angels OrtizMaria MuletSílvia VidalMargarita Majem
- [49] The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 1823 - 1835Zamora Atenza, CarlosAnguera, GeorgiaRiudavets Melia, MarionaAlserawan De Lamo, LeticiaSullivan, IvanaBarba Joaquin, AndresSerra Lopez, JorginaAngels Ortiz, M.Mulet, MariaVidal, SilviaMajem, Margarita
- [50] Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials[J]. ONCOLOGIST, 2024, : 422 - 430Vallejo, JonathonSingh, HarpreetLarkins, ErinDrezner, NicoleRicciuti, BiagioMishra-Kalyani, PallaviTang, ShenghuiBeaver, Julia A.Awad, Mark M.